Zacks Investment Research lowered shares of American Renal Associates Holdings Inc. (NYSE:ARA) from a hold rating to a sell rating in a report published on Tuesday morning.

According to Zacks, “American Renal Associates Holdings, Inc. is a provider of dialysis services primarily in the United States. It also offers outpatient and inpatient dialysis treatments for patients suffering from chronic kidney failure. American Renal Associates Holdings, Inc. is based in Beverly, Massachusetts. “

ARA has been the subject of a number of other reports. Leerink Swann reissued an outperform rating on shares of American Renal Associates Holdings in a report on Sunday, August 21st. Barclays PLC restated a buy rating and set a $31.00 price target on shares of American Renal Associates Holdings in a research report on Thursday, August 18th. Bank of America Corp. restated a buy rating and set a $35.00 price target on shares of American Renal Associates Holdings in a research report on Monday, August 22nd. Finally, Wells Fargo & Co. restated a buy rating on shares of American Renal Associates Holdings in a research report on Sunday, September 25th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $31.17.

Analyst Recommendations for American Renal Associates Holdings (NYSE:ARA)

American Renal Associates Holdings (NYSE:ARA) opened at 17.58 on Tuesday. The stock’s market cap is $542.66 million. The stock has a 50 day moving average price of $19.59 and a 200-day moving average price of $24.43. American Renal Associates Holdings has a 12 month low of $17.43 and a 12 month high of $29.65.

American Renal Associates Holdings (NYSE:ARA) last issued its earnings results on Tuesday, August 9th. The company reported ($0.75) earnings per share (EPS) for the quarter. The firm earned $185.60 million during the quarter, compared to analyst estimates of $161.50 million. On average, analysts expect that American Renal Associates Holdings will post $0.95 EPS for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Centerbridge Partners L.P. purchased a new position in shares of American Renal Associates Holdings during the second quarter worth approximately $510,331,000. FMR LLC purchased a new position in shares of American Renal Associates Holdings during the second quarter worth approximately $53,347,000. TimesSquare Capital Management LLC bought a new position in American Renal Associates Holdings during the second quarter valued at about $30,708,000. Janus Capital Management LLC bought a new position in American Renal Associates Holdings during the second quarter valued at about $24,016,000. Finally, Vanguard Group Inc. bought a new position in American Renal Associates Holdings during the second quarter valued at about $17,327,000. Hedge funds and other institutional investors own 85.20% of the company’s stock.

American Renal Associates Holdings Company Profile

American Renal Associates Holdings, Inc is a dialysis services provider in the United States. The Company focuses on joint venture partnerships with physicians. The Company’s segment is the ownership and operation of dialysis clinics. It provides patient care and clinical outcomes to patients suffering from the advanced stage of chronic kidney disease, known as end stage renal disease (ESRD).

5 Day Chart for NYSE:ARA

Receive News & Stock Ratings for American Renal Associates Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates Holdings Inc. and related stocks with our FREE daily email newsletter.